RFCA
PTLA

R&F Capital Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

R&F Capital Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$253K Buy
+6,459
New +$206K 0.07% 461

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

R&F Capital Advisors's PTLA Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Portola Pharmaceuticals, Inc. (PTLA) in Q1 2017: 6,459 shares worth $253K. The stake represents 0.07% of the portfolio and ranks #461 among its holdings.

180 funds tracked by Wall St. Rank hold PTLA as of Q1 2017.

  • R&F Capital Advisors held 6,459 shares of Portola Pharmaceuticals, Inc. worth $253K as of Q1 2017.
  • Portola Pharmaceuticals, Inc. was a new R&F Capital Advisors position in Q1 2017.
  • Portola Pharmaceuticals, Inc. made up 0.07% of R&F Capital Advisors's portfolio in Q1 2017, its #461 holding.
  • 180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.